Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia

TOKYO, April 23, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) today announced that it submitted on March 23, 2018, a new drug application (NDA) for marketing approval of gilteritinib...
Source: - New Drug Applications - Category: Drugs & Pharmacology Source Type: news

Related Links:

CAR T-cell therapy has proven to be a highly effective, breakthrough therapy for treating acute lymphoblastic leukemia and acute myeloid leukemia. Here, Nikhil Munshi, MD, from the Dana-Farber Cancer ... Author: VJHemOnc Added: 07/16/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
(Comprehensive Cancer Centre Gustave Roussy) For the first time, a team of international researchers have mapped the family trees of cancer cells in acute myeloid leukemia (AML) to understand how this blood cancer responds to a new drug, enasidenib. The work also explains what happens when a patient stops responding to the treatment, providing important clues about how to combine enasidenib with other anti-cancer drugs to produce longer-lasting remissions and to prevent relapse.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
The association between Wilms tumor 1 (WT1) expression, genetic abnormalities and homozygous single polymorphism (SNP) in WT1 gene was evaluated in 252 acute myelogenous leukemia (AML) patients. WT1 expression correlated with prognostic genetic abnormalities. Homozygous WT1 SNP rs16754 was associated with lower expression of WT1. WT1 expression had no prognostic impact in any cytogenetic group or SNP status.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
We compared outcomes for patients with acute myeloid leukemia (AML) with intermediate risk karyotype receiving consolidation with: autologous stem cell transplant (autoSCT), matched sibling and unrelated allogeneic SCT (alloSCT) or chemotherapy. Consolidation with sibling alloSCT provided the best outcome. The long-term outcomes of autoSCT were comparable to unrelated alloSCT.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
We presently forget 98% of everything we experience. That will go away in favor of perfect, controllable, configurable memory. Skills and knowledge will become commodities that can be purchased and installed. We will be able to feel exactly as we wish to feel at any given time. How we perceive the world will be mutable and subject to choice. How we think, the very fundamental basis of the mind, will also be mutable and subject to choice. We will merge with our machines, as Kurzweil puts it. The boundary between mind and computing device, between the individual and his or her tools, will blur. Over the course of the ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Therapy related myeloid neoplasm (t-MN) is an emerging challenge in the current era given that newer therapies are improving the life expectancy of patients diagnosed with cancer. This condition arises as a result of exposure to prior chemotherapy or radiotherapy used to treat malignant or non-malignant conditions. The World Health Organization (WHO) 2001 classification of tumors of hematopoietic and lymphoid tissues had initially described this disorder with two subtypes – therapy related acute myeloid leukemia (t-AML) and therapy related myelodysplastic syndrome (t-MDS) 1.
Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research
Relapse is the most important cause of failure in the treatment of acute myeloid leukemia (AML). The European Leukemia Net (ELN) recommends allogeneic stem cell transplantation (alloSCT) in AML patients in first complete remission after a careful risk-benefit assessment1. Here, disease specific and transplantation specific risk factors have to be evaluated before a recommendation for an alloSCT can be given. Generally, alloSCT is recommended if disease relapse risk exceeds 35 to 40% without the procedure.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
This study provides insight into the role of MLL-AF9 in zebrafish hematopoiesis and establishes a robust and efficient in vivo model for high-throughput drug screening. PMID: 30003105 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Tags: Biomed Res Int Source Type: research
Condition:   Acute Myeloid Leukemia Interventions:   Drug: Azacitidine;   Drug: Cladribine;   Drug: Cytarabine;   Drug: Venetoclax Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: - Category: Research Source Type: clinical trials
The glycoprotein CD56, also known as a neural cell adhesion molecule (NCAM), plays an important role in normal physiological functions.   It is expressed in low levels in normal cells such as neurons, glia, skeletal muscle and natural killer cells. It is highly expressed on a variety of cancerous cells including those of neuroblastoma, small-cell lung cancer, and multiple myeloma.  In neuroblastoma, patients undergo a very aggress ive standard of care regimen that results in a high mortality rate.  Many neuroblastomas have increased expression of CD56, which represents a possible therapeutic target for these...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Drugs & Pharmacology | Leukemia | Marketing | New Drug Applications | Pharmaceuticals